多尼培南研究综述
摘要
本文对多尼培南的临床应用包括已上市药品的适应症、市场销售、注册报批方面进行了综述,指出了开发多尼培南前景广阔,利润巨大。
出处
《生物技术世界》
2014年第3期84-84,共1页
Biotech World
二级参考文献21
-
1DAVIES T A, SHANG W C, BUSH K, et al. Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and pseudomonas aeruginosa [ J ]. Antimicrob Agents Chemother , 2008,52 (4) :1510-1512.
-
2FUJ1MURA T, KIMURA Y . In vitro antibacterial activity of doripenem, a novel parenteral carbapenem [ J ]. Jpn J Chemother,2005, 53 ( S-1 ) : S57 - S70.
-
3TSUJI M, ISHII Y, OHNO A, et al. In vitro and in vivo antibacterial activities of S-d661, a new carbapenem [ J ]. Antimicrob Agents Chemother, 1998,42 ( 1 ) :94 - 99.
-
4GE Y,WIKLER M A,SAHM D F, et al. In vitro antimicrobial activity of doripenem, a new carbapenem [ J ]. Antimicrob Agents Chemother,2004,48 ( 4 ) : 1384 - 1396.
-
5GOLDSTEIN E J C, CITRON D M, MERRIAM C V, et al. In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds [ J ]. A ntimicrob Agents Chemother,2008,52 ( 2 ) :761 - 766.
-
6TRACZEWSKI M M, BROWN S D. In vitro activity of doripenem against pseudomonas aeruginosa and burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients [ J ]. Antimicrob Agents Chemother, 2006, 50 ( 2 ) :819 - 821.
-
7MUSHTAQ S, GE Y, LIVERMORE D M. Doripenem versus pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants,and transconjugants and resistance selection potential [ J]. Antimicrob Agents Chemother, 2004,48 ( 8 ) : 3086 - 3092.
-
8SHIONOGI CO, LTD. Doribax TM (doripenem for injection ) [ EB/ OL]. 2008 [ 2008-09-16 ]. http://www. doribax.com/doribax/ interactive_pi.html.
-
9LUCASTI C, JASOVICH A, UMEH O, et al. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection : a phase III, prospective,multicenter, randomized, double-blind, noninferiority study [ J ]. Clin Ther,2008,30 ( 5 ) :868 - 883.
-
10KAMIDONO S, ARAKAWA S. Double-blind, controlled study to evaluate safety and efficacy of doripenem and meropenem in patients with complicated urinary tract infection [ J ]. Jpn J Chemother,2005, 53 ( S-1 ) :244 - 259.
-
1朱雪焱,袁哲东.碳青霉烯类抗生素多尼培南及其临床应用[J].世界临床药物,2006,27(9):537-540. 被引量：4
-
2冯建秋.100个化学药品市场销售情况调查[J].医药情报,1992(4):30-31.
-
3张跃.前景广阔的氟喹诺酮类抗生素[J].开卷有益,1992(2):46-47.
-
4国家药品监督管理局令 第6号[J].中国药事,1999,13(3):147-150.
-
5丁鼎乐,樊生华.靶向制剂国内外研究进展[J].中国医药情报,1996,2(5):301-302. 被引量：4
-
6覃卓明.左旋氧氟沙星的临床药代动力学研究综述[J].世界医学杂志,1999,3(9):89-94. 被引量：3
-
7药品注册管理办法（试行）[J].经济管理文摘,2003(3):42-48.
-
8陈玉辉.关于米氮平耐受性和安全性的研究综述[J].中国民康医学,2004,16(12):760-762. 被引量：3
-
9张伦.阿米卡星市场浅析[J].中国制药信息,2011,27(1):25-27.
-
10王盈.全球药品研发进展(2012.10)[J].中国医药工业杂志,2013,44(7).
